News briefing: Ziopharm drama continues with new letter from activist group; Alnylam, Centogene join forces on ATTRv screening program
As Friday’s deadline to submit written consent approaches, WaterMill Asset Management Corp is continuing to put the pressure on Ziopharm Oncology in its activist attack.
The 3.3% minority stakeholder sent a new letter to investors Tuesday morning, emphasizing the need for boardroom change ahead of the self-imposed due date. WaterMill again pushed for the full slate of its three board nominees — Jaime Vieser, Holger Weis and WaterMill founder Robert Postma — to be selected, and detailed numerous accounts of what it says are attempts by Ziopharm to “distort” the truth.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.